Advertisement

Hepatitis D Virus Infection: Role of Hepatitis B and the Current Updates on Management

  • Abdulmajeed A. Albarrak
  • Ky-Dieu Tran
  • Veysel Tahan
Chapter

Abstract

Hepatitis D virus (HDV) discovery was linked to hepatitis B virus (HBV), where it was named as delta antigen and thereafter found to be the smallest RNA virus but a genome by itself depending of hepatitis B in its life cycle. It uses hepatitis B surface antigen as envelope and uses similar mechanism to enter the hepatocyte. Once inside the hepatocyte, it uses the host cell enzymes to replicate. HDV has eight genotypes with variation in geographic location and clinical severity. Also, certain HBV genotypes are linked with higher viral load and lower remission rates. Chronic hepatitis D (CHD) can result from either coinfection or superinfection of HBV, the latter associated with higher rate of progression to CHD. Pegylated interferon has been the mainstay treatment for CHD for many years with discouraging virological response around 25%. Recent trails of new medications including myrcludex B, lonafarnib, and nucleic acid polymers show some promising results awaiting further larger trials.

Keywords

Hepatitis D Delta Genotype Life cycle Coinfection Superinfection Therapy Treatment 

References

  1. 1.
    Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997–1003.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Smedile A, Rizzetto M. HDV: thirty years later. Dig Liver Dis. 2011;43(Suppl 1):S15–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8 Suppl:S10–4. discussion S21–3.CrossRefPubMedGoogle Scholar
  4. 4.
    Ahn J, Gish RG. Hepatitis D virus: a call to screening. Gastroenterol Hepatol (N Y). 2014;10:647–86.Google Scholar
  5. 5.
    Amini N, Alavian SM, Kabir A, Aalaei-Andabili SH, Saiedi Hosseini SY, Rizzetto M. Prevalence of hepatitis d in the eastern Mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13:e8210.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat. 2011;18:518–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Rizzetto M, Alavian SM. Hepatitis delta: the rediscovery. Clin Liver Dis. 2013;17:475–87.CrossRefPubMedGoogle Scholar
  8. 8.
    Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32:211–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, Winters MA, Proudfoot J, Glenn JS. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol. 2013;28:1521–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Deny P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol. 2006;307:151–71.PubMedGoogle Scholar
  11. 11.
    Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, Lee PC, Lee SD, Wu JC. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130:1625–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Wu JC, Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet. 1995;346:939–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Casey JL, Niro GA, Engle RE, Vega A, Gomez H, McCarthy M, Watts DM, Hyams KC, Gerin JL. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis. 1996;174:920–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Makuwa M, Caron M, Souquiere S, Malonga-Mouelet G, Mahe A, Kazanji M. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in Central Africa. J Clin Microbiol. 2008;46:754–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Kiesslich D, Crispim MA, Santos C, Ferreira Fde L, Fraiji NA, Komninakis SV, Diaz RS. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J Infect Dis. 2009;199:1608–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Lin JH, Chang MF, Baker SC, Govindarajan S, Lai MM. Characterization of hepatitis delta antigen: specific binding to hepatitis delta virus RNA. J Virol. 1990;64:4051–8.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. 2016;64:S102–S16.CrossRefPubMedGoogle Scholar
  18. 18.
    Weiner AJ, Choo QL, Wang KS, Govindarajan S, Redeker AG, Gerin JL, Houghton M. A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol. 1988;62:594–9.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol. 2012;1:71–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: a review. World J Hepatol. 2013;5:666–75.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife. 2012;1:e00049.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, Sultmann H, Urban S. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146:1070–83.CrossRefPubMedGoogle Scholar
  23. 23.
    Huang CR, Lo SJ. Evolution and diversity of the human hepatitis d virus genome. Adv Bioinforma. 2010;2010:323654.CrossRefGoogle Scholar
  24. 24.
    Lai MM. The molecular biology of hepatitis delta virus. Annu Rev Biochem. 1995;64:259–86.CrossRefPubMedGoogle Scholar
  25. 25.
    Rizzetto M. The adventure of delta. Liver Int. 2016;36(Suppl 1):135–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Casey JL. RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol. 2006;307:67–89.PubMedGoogle Scholar
  27. 27.
    Otto JC, Casey PJ. The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells. J Biol Chem. 1996;271:4569–72.CrossRefPubMedGoogle Scholar
  28. 28.
    Greco-Stewart V, Pelchat M. Interaction of host cellular proteins with components of the hepatitis delta virus. Viruses. 2010;2:189–212.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Patient R, Hourioux C, Sizaret PY, Trassard S, Sureau C, Roingeard P. Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking. J Virol. 2007;81:3842–51.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010;17:749–56.CrossRefPubMedGoogle Scholar
  31. 31.
    Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, Vergani D, Williams R, Rizzetto M. Influence of delta infection on severity of hepatitis B. Lancet. 1982;2:945–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Govindarajan S, Chin KP, Redeker AG, Peters RL. Fulminant B viral hepatitis: role of delta agent. Gastroenterology. 1984;86:1417–20.PubMedGoogle Scholar
  33. 33.
    Chen PJ, Chen DS, Chen CR, Chen YY, Chen HM, Lai MY, Sung JL. Delta infection in asymptomatic carriers of hepatitis B surface antigen: low prevalence of delta activity and effective suppression of hepatitis B virus replication. Hepatology. 1988;8:1121–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Arico S, Calzia R, Picciotto A, Colombo M, Popper H. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. 1983;98:437–41.CrossRefPubMedGoogle Scholar
  35. 35.
    Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629–38.CrossRefPubMedGoogle Scholar
  36. 36.
    Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46:420–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology. 1991;13:1052–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver. 1995;15:45–52.CrossRefPubMedGoogle Scholar
  39. 39.
    Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, Ilter T, Batur Y. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10:721–6.PubMedGoogle Scholar
  40. 40.
    Yurdaydin C, Idilman R. Therapy of delta hepatitis. Cold Spring Harb Perspect Med. 2015;5:a021543.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gurel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H, HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87–97.CrossRefPubMedGoogle Scholar
  42. 42.
    Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP, HIDIT-1 Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31.CrossRefPubMedGoogle Scholar
  43. 43.
    Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, Midilli K, Ozbay G. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol. 2006;21:657–63.CrossRefPubMedGoogle Scholar
  44. 44.
    Wedemeyer H, Yurdaydin C, Ernst S, Caruntu F, Carercu M, Kendal K, Akarca US, Selium G, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Onur K, Port K, Celen MK, Stift J, Heidrich B, Mederacke I, Hardtke S, Koch A, Dienes HP, Manns MP. 96 weeks of pegylated-interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Hepatology. 2013;58:222–3.CrossRefGoogle Scholar
  45. 45.
    Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147:48–64.CrossRefPubMedGoogle Scholar
  46. 46.
    Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65:490–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Glenn JS. Prenylation of HDAg and antiviral drug development. Curr Top Microbiol Immunol. 2006;307:133–49.PubMedGoogle Scholar
  49. 49.
    Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167–74.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Yurdaydin C, Idilman R, Keskin O, Kalkan C, Karakaya MF, Caliskan A, Yurdcu E, Karatayli SC, Bozdayi M, Koh C, Heller T, Glenn J. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study. J Hepatol. 2017;66:S33–S4.CrossRefGoogle Scholar
  51. 51.
    Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob Agents Chemother. 2013;57:5291–8.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Al-Mahtab M, Bazinet M, Vaillant A. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One. 2016;11:e0156667.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Bazinet M, Pantea V, Placinta G, Moscalu I, Cebotarescu V, Cojuhari L, Jimbei P, Iarovoi L, Smesnoi V, Musteata T, Jucov A, Krawczyk A, Vaillant A. Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection. J Hepatol. 2017;66:S256–S7.CrossRefGoogle Scholar
  54. 54.
    Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Krawczyk A, Karimzadeh H, Roggendorf M, Vaillant A. FRI-105 - update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2A in caucasian patients with chronic HBV/HDV co-infection. J Hepatol. 2016;64:S584–S5.CrossRefGoogle Scholar
  55. 55.
    Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Vaillant A. LBP-507 - one year follow-up and HBV RNA/HBcrAg analysis in the REP 301 trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV/HDV co-infection. J Hepatol. 2017;66:S96–S7.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Abdulmajeed A. Albarrak
    • 1
  • Ky-Dieu Tran
    • 1
  • Veysel Tahan
    • 1
  1. 1.Division of Gastroenterology and HepatologyUniversity of MissouriColumbiaUSA

Personalised recommendations